CLL Microlearning Series – Video #7: Empowering Patients Through Choice and Communication
Empowering Patients Through Choice and Communication
Adherence is essential for the long-term effectiveness of zanubrutinib, an oral BTK inhibitor taken indefinitely until progression or intolerance.
In this video, an APP specializing in CLL discusses how proactive communication, side-effect counseling, and strong clinician–patient rapport can help identify and address barriers to adherence early.
You’ll Learn:
- Why adherence is critical for the sustained effectiveness of long-term zanubrutinib therapy
- How untreated or bothersome side effects can lead to missed doses
- Ways clinicians can support adherence through ongoing counseling and expectation-setting
- The importance of open communication to uncover intentional or unintentional missed doses
- Practical strategies to improve adherence, such as reminders, support-person involvement, and early identification of financial or tolerability issues
- How multidisciplinary teamwork (APPs, pharmacists, nurses, and physicians) helps resolve adherence barriers quickly
More from this series
CLL Microlearning: Setting the Stage for Treatment Decisions in CLL
This segment outlines the key patient and disease characteristics that inform when—and how—to approach therapy in a thoughtful, individualized way.
January 12, 2026
CLL Microlearning: Considerations for 1st Line Therapy
This short module highlights the practical, real-world cues that signal true disease progression—ensuring therapy begins at the appropriate time and for the right reasons. An APP specializing in CLL walks through how to interpret clinical symptoms, lab trends, and iwCLL criteria in everyday practice.
November 13, 2025
CLL Microlearning: Why Zanubrutinib is a Meaningful Option
This segment highlights why zanubrutinib has emerged as a meaningful choice in frontline and relapsed CLL, especially for older adults and those with cardiovascular comorbidities who may be more vulnerable to off-target toxicities.
November 13, 2025
CLL Microlearning: Practical Aspects of Prescribing Zanubrutinib
This video covers the key practical details clinicians should know when prescribing zanubrutinib. As a second-generation BTK inhibitor, it offers effective disease control with a flexible dosing schedule that can be tailored to patient needs.
November 13, 2025
CLL Microlearning: Managing Common Side Effects
In this video, an APP specializing in CLL reviews the most common symptoms patients report and shares practical strategies clinicians can use to support management and keep patients on therapy.
November 13, 2025
CLL Microlearning: Zanubrutinib’s Cardiovascular Profile
In this video, an APP specializing in CLL explains how zanubrutinib compares to other BTK inhibitors and outlines practical steps clinicians can take to evaluate and manage cardiovascular risk.
November 13, 2025
CLL Microlearning: Personal Insights and Practice-Based Learning
In this video, an APP specializing in CLL reflects on how newer options—particularly zanubrutinib—support more individualized care by balancing efficacy, safety, and patient preferences.
November 13, 2025